Active, not recruitingPhase 3NCT05463731

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eli Lilly and Company
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Intervention
Remternetug (IV)(drug)
Enrollment
1667 target
Eligibility
60-85 years · All sexes
Timeline
20222026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05463731 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease

← Back to all trials